{"disease":{"id":"high-risk-hematologic-disorders","name":"high risk hematologic disorders"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03367546","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}